Clinical

These indications cover HIV, type 1 diabetes, chronic hives, genetic-related hearing loss, and lupus.

Ez-PAVE delivers the first direct trial evidence that targeting LDL below 55 mg/dL is superior to below 70 mg/dL in ASCVD patients—providing proof of concept for treat-to-target strategies and a wake-up call about clinical inertia.

Systemic therapy for CSCC is evolving toward earlier use, combination and de-escalation strategies, and biomarker-driven personalization to improve outcomes and reduce toxicity.

Long-acting therapies could be key to engaging unsuppressed patients and closing persistent gaps in HIV care.

Landmark analyses from VESALIUS-CV reveal that the cardiovascular benefits of intensive LDL lowering build meaningfully over time in primary prevention—reinforcing the "lower for longer" principle and pointing toward lower LDL targets for high-risk diabetic patients.

Fatima Cody Stanford, MD, MPH, MPA, exposes obesity health disparities, GLP-1 access hurdles, payer policy fixes, and how stigma in care blocks equitable treatment.

Panelists examine the societal impact of stroke by outlining its prevalence, underlying pathophysiology, key modifiable risk factors, and the substantial clinical, economic, and long-term disability burden it places on patients and the healthcare system.

Panelists explore stroke classification and clinical presentation, highlighting key differences between ischemic and hemorrhagic strokes, the TOAST system for subtype identification, and the importance of understanding underlying causes to guide diagnosis and long-term management.

Poor housing affordability and quality raised risks of frailty, disability, and death in older adults, yet neighborhood quality showed no independent association.

New data show how systemic inflammation independently raises the risk of CKD progression and cardiovascular events after acute myocardial infarction.

At NAACOS 2026, experts highlighted how real-world AI tools are improving care delivery, outcomes, and efficiency across the health care landscape.

Marc P. Bonaca, MD, MPH, and Josephine Harrington, MD, discuss the clinical value of the uACR test and why it remains underutilized.

Education on colorectal cancer symptoms and screening can help to prevent advancing disease in a cancer that is seeing increased incidence in younger adults.

A phase 3b trial demonstrates that tildrakizumab meets robust efficacy endpoints for nail psoriasis—an historically difficult manifestation to treat—while maintaining a favorable long-term safety profile through week 72.

FIT-DNA modestly improved CRC screening in CHCs, but uptake and follow-up colonoscopy rates remained low.

Patients with advanced glaucoma had better outcomes when treated with trabeculectomy rather than using medication first.

Wastewater SARS-CoV-2 levels correlated with hospital COVID-19 cases, supporting targeted screening of asymptomatic patients.

The BCBSNC Foundation's focus on access to care, health through food, and youth mental health aligns with broader national health trends.

Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal metabolic effects.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

Behavioral text nudges outperformed nurse calls, boosting FIT completion by 9 percentage points at an FQHC while saving staff time.

Multidisciplinary collaboration is essential in managing high-risk CSCC, helping clinicians overcome logistical barriers to deliver coordinated, individualized care.

VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for intensive LDL lowering well before a first event.

Beyond standard risk scores, the guideline highlights key risk enhancers—including lipoprotein(a), inflammation markers, and women's health factors—and elevates coronary artery calcium scoring as a Class I tool for resolving uncertainty in primary prevention.

Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.